AGE

AgeX Therapeutics
AMEX

Real-time Quotes | Nasdaq Last Sale

0.9155
+0.0005
+0.05%
Closed 16:00 09/18 EDT
OPEN
0.9300
PREV CLOSE
0.9150
HIGH
0.9500
LOW
0.8870
VOLUME
106.15K
TURNOVER
--
52 WEEK HIGH
2.500
52 WEEK LOW
0.6660
MARKET CAP
34.50M
P/E (TTM)
-2.9193
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Rockwell Medical Announces Appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer and Chief Business Officer
WIXOM, Mich., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced
GlobeNewswire · 5d ago
Newgioco Obtains GLI-33 Certification To Launch Elys Sportsbook Platform In U.S.
AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes AgeX Secures Independence to License out ESI Cell
Benzinga · 09/09 12:29
AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes
AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a company focused on developing and commercializing innovative therapeutics for human aging, and Lineage Cell Therapeutics, Inc. ("Lineage": NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel
Business Wire · 09/09 12:00
Lineage Cell receives $24.6M payment; strong cash runway
Lineage Cell Therapeutics (LCTX) +1.4% PM, received $24.6M in cash from Juvenescence, representing principal and interest due under a convertible promissory note; August 2018 note issued as partial payment for the sale by
Seekingalpha · 08/31 13:22
AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
Business Wire · 08/14 21:05
AgeX Therapeutics reports Q2 results
AgeX Therapeutics (AGE): Q2 GAAP EPS of -$0.07.Revenue of $0.41M (+7.9% Y/Y)Shares +2.5%.Press Release
Seekingalpha · 08/14 20:12
AgeX broadens access to stem cell lines with Pluristyx deal
Seeking Alpha - Article · 06/16 13:27
AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
Business Wire · 06/16 13:00
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Institutional Holdings
Institutions: 54
Institutional Holdings: 6.40M
% Owned: 16.98%
Shares Outstanding: 37.69M
TypeInstitutionsShares
Increased
21
998.73K
New
9
146.44K
Decreased
7
89.35K
Sold Out
14
763.59K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.06%
Pharmaceuticals & Medical Research
+0.57%
Key Executives
Chairman/Independent Director
Gregory Bailey
Chief Executive Officer/Founder/Director
Michael West
Chief Financial Officer
Andrea Park
Vice President - Research & Development
Hal Sternberg
Independent Director
Annalisa Jenkins
Independent Director
Michael May
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AGE
AgeX Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AgeX Therapeutics Inc stock information, including AMEX:AGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGE stock methods without spending real money on the virtual paper trading platform.